Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)

June 16, 2026 9:00 AM

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $52.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found